Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin;Massive blutungsneigung bei zwei patienten mit faktor-V-hemmkörper und anti-phospholipid-antikörpern nach ciprofloxacin-einnahme

Medizinische Klinik

Volumn 98, Issue 6, 2003, Pages 339-343

  Miesbach, Wolfgang ^a   Voigt, Jochen ^b   Peetz, Dirk ^c   Scharrer, Inge ^a  

^a GOETHE UNIVERSITY   (Germany)

^b St Vinzenz und Elizabeth Hospital   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Antiphospholipid antibodies; Ciprofloxacin; Factor V inhibitor; Prolonged aPTT

Indexed keywords

ACETYLDIGOXIN; AMBROXOL; AUTOANTIBODY; BENAZEPRIL; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 ANTIBODY; CEFTRIAXONE; CIPROFLOXACIN; CLONIDINE; DIHYDRALAZINE; DIPYRONE; FUROSEMIDE; HEPARIN; METHYLPREDNISOLONE; METOCLOPRAMIDE; NIFEDIPINE; PHOSPHOLIPID ANTIBODY; PRAVASTATIN; STEROFUNDIN; UNCLASSIFIED DRUG;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CASE REPORT; DISEASE SEVERITY; HUMAN; MALE; MUSCLE BLEEDING; PARTIAL THROMBOPLASTIN TIME; PNEUMONIA; POSTOPERATIVE INFECTION; PROTHROMBIN TIME; SEPSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 0037775904     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1268-7     Document Type: Article

References (34)

1. Hultin MB. Acquired inhibitors in malignant and non malignant diseases states. Am J Med 1991; 1:9S-13S.
2. Okajima A, Horii J, Nasu K, Niki Y, Akasaka K, Yamashita H, Sugi M, Yoshioka A. Factor V inhibitor with double cancer. Rinsho Ketsueki 1989; 30:514-9.
3. Bayani N, Rugina M, Haddad-Vergnes L, Lelong F. High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol 2002;71:33-6.
4. Coots MC, Mühleman AF, Glueck HI. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 1978;4:193-206.
5. Feinstein DI, Rapaport SI, Chong MM. Factor V inhibitor: a report of a case, with comments on a possible effect of streptomycin. Ann Intern Med 1973; 78:385-8.
6. Stenbjerg S, Husted S, Mygind K. A circulating factor V inhibitor: possib]e side effect of treatment with streptomycin. Scand J Haematol 1975;14:280-5.
7. Thomas F, Rpbert A, Luquel L, Dombret H, Offenstadt G, Amstutz P. Lethal hemorrhagic syndrome after mithramycin. Lack ofplatelet aggregation and inhibitor of factor V [Letter]. Presse Med 1989;18:182.
8. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68:366-74.
9. Kaspar CK. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh 1975; 34:869.
10. Mackie IJ, Donohoe S, Machin SJ. Lupus anticoagulant measurement. In: Khamashta MA, ed. Hughes syndrome - antiphospholipid syndrome. London-Berlin-Heidelberg: Springer, 2000:214-25.
11. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986;68:869-74.
12. Triplett DA, Stocker KF, Unger GA. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993;70:925-31.
13. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating activity. Thromb Haemost 1987;57:144-7.
14. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;ii:1211-4.
15. Whitten CW, Greilich PE. Thrombelastography: past, present, and future. Anesthesiology 2000;92: 1223-5.
16. Knobl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998;11:305-18.
17. Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, Bowie EJW. Isolation and study of an acquired inhibitor ofhuman anticoagulation factor V. J Clin Invest 1986;77:405-15.
18. Feinstein DI. Acquired inhibitors of factor V. Thromb Haemost 1978;39:663-74.
19. Heuline A, Siame JL, Jude B, Parquet A. Anti-factor V acquired circulating anticoagulant in rheumatoid arthritis [Letter]. Rev Rhum Mal Osteoartic 1990; 57:442.
20. Koyama T, Saito T, Kusano T, Kirosawa S. Factor V inhibitor associated with Sjögren's syndrome. Br J Haematol 1995:89:893-6.
21. Van Spronsen DJ, Oosting JD, Hoffmann JJML, Breed WPM. Factor V inhibitor associated with cold agglutinin disease. Ann Hematol 1998;76:49-50.
22. Denis A, Baudeau C, Verdy E, Couderc C, Ramdeau E, Srar JD. Acquired circulating anticoagulant with anti-factor V activity in AIDS. First case report. Nouv Rev Fr Hematol 1995;37:165-7.
23. Van Beek EJR, Peters M, ten Cate JW. Factor VIII inhibitor associated with ciprofloxacin. Thromb Haemost 1993;69:403.
24. Castaman Rodeghiero F. Acquired transitory, von Willebrand syndrome with ciprofloxacin. Lancet 1994;343:492.
25. Choe U, Rothschild BM, Laitman L. Ciprofloxacin-induced vasculitis. N Engl J Med 1989;320:257-8.
26. Kanuga J, Holland CL, Reyes R, Bielory L. Ciprofloxacin induced leukocytoclastic vasculitis with cryoglobulinemia. Ann Allergy 1991;66:76. abstract.
27. Stubbings J, Sheehan-Dare R, Walton S. Cutaneous vasculitits due to ciprofloxacin. Br Med J 1992; 305:29.
28. Kapur A, Kelsey PR, Isaacs PET. Factor V inhibitor in thrombosis. Am J Hematol 1993;42:384-8.
29. Kamphuisen PW, Haan J, Rosekrans PCM, van der Meer FJM. Deep-vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus-like features. Am J Hematol 1998;57:176-8.
30. George S, Nagabhushana MS, Cyran EM. Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis [Letter]. Am J Hematol 1995; 49:98-100.
31. Scharrer I, Fürstenau C, Stotz D, Müller-Beissenhirtz W, Ehrenforth S, Depka Prondzinski M von, Siegert S. Auftreten eines Faktor V-Hemmkörpers und Auftreten von Lupus-Antikoagulanzien nach Ciprofloxacin. In: Scharrer I, Schramm W. Hrsg. 25. Hämophilie-Symposium Hamburg 1994. Berlin-Heidelberg: Springer, 1996:388-92.
32. Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988;71:539-55.
33. Wang MX, Kandiah DA, Ichiwaka K, Khamashta M, Hughes G, Koike T. Roubey R, Krilis SA. Epitope specifity of monoclonal anti-beta 2-glycoprotein-1 antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995;155:1629-36.
34. Jimenez-Valera M, Sampedro A, Moreno E, Ruiz-Bravo A. Modification of immune response in mice by ciprofloxacin. Antimicrob Agents Chemother 1995;39:150-4.